Receptor-based targeting of therapeutics

Therapeutic Delivery

Volumn 4, Issue 3, 2013, Pages 369-394

  Mehra, Neelesh Kumar ^a   Mishra, Vijay ^a   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; CARBON NANOTUBE; CETUXIMAB; DENDRIMER; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; FOLATE RECEPTOR; GEMCITABINE; HYALURONAN RECEPTOR; INTEGRIN; INTEGRIN RECEPTOR; LACTOFERRIN; LAPATINIB; LECTIN RECEPTOR; LIPOSOME; METHOTREXATE; PACLITAXEL; PERTUZUMAB; RECEPTOR PROTEIN; SCAVENGER RECEPTOR; TAMOXIFEN; TRANSFERRIN RECEPTOR; TRASTUZUMAB; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; BREAST CANCER; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG RELEASE; DRUG TARGETING; ENDOCYTOSIS; GLIOMA; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PARTICLE SIZE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; REVIEW; STOMACH ADENOCARCINOMA; TUMOR VOLUME; ZETA POTENTIAL;

EID: 84874591329     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.13.6     Document Type: Review

References (194)

1. Jain K, Kesharwani P, Gupta U, Jain NK. A review of glycosylated carriers for drug delivery. Biomaterials 33(16), 4166-4186 (2012).
2. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60, 1615-1626 (2008).
3. Agarwal A, Saraf S, Asthana A, Gupta U, Gajbhiye V, Jain NK. Ligand based dendritic systems for tumor targeting. Int. J. Pharm. 350, 3-13 (2008).
4. Nahta R, Esteva FJ. Herceptin: mechanisms of action and resistance. Cancer Lett. 232, 123-138 (2006).
5. Arya G, Vandana M, Acharya S, Sahoo SK. Enhanced antiproliferative activity of Herceptin (HER2)-conjugated gemcitabine-loaded chitosan nanoparticle in pancreatic cancer therapy. Nanomedicine 7, 859-870 (2011).
6. Gupta P, Srivastava SK. Anti-tumor activity of phenethyl isothiocyanate in HER2 positive breast cancer models. BMC Med. 10, 80 (2012).
7. Ahmed N, Salsman VS, Kew Y et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin. Cancer Res. 16 474-485 (2010).
8. Taheri A, Dinarvand R, Atyabi F, Ghahremani MH, Ostad SN. Trastuzumab decorated methotrexate-human serum albumin conjugated nanoparticles for targeted delivery to HER2 positive tumor cells. Eur. J. Pharm. Sci. 47, 331-340 (2012).
9. Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials 33, 1627-1639 (2012).
10. Liu Z, Sun X, Nakayama-Ratchford N et al. Supramolecular chemistry on water soluble carbon nanotubes for drug loading and delivery. ACS Nano 1(1), 50-56 (2007).
11. Singh P, Gupta U, Asthana A, Jain NK. Folate and folate-PEG-PAMAM dendrimers: synthesis, characterization, and targeted anticancer drug delivery potential in tumor bearing mice. Bioconjug. Chem. 19, 2239-2252 (2008).
12. Gupta U, Dwivedi SKD, Bid HK, Konwar R, Jain NK. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int. J. Pharm. 393,185196 (2010).
13. Patel SK, Gajbhiye V, Jain NK. Synthesis, characterization and brain targeting potential of paclitaxel loaded thiamine-PPI nanoconjugates. J. Drug Target. 20(10), 841 (2012).
14. Lu YJ, Wei KC, Ma CCM, Yang SY, Chen JP. Dual targeted delivery of doxorubicin to cancer cells using folate-conjugated magnetic multi-walled carbon nanotubes. Colloids Surf. B Biointerfaces 89, 1-9 (2012).
15. Daniels TR, Bernabeu E, Rodriguez JA et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim. Biophys. Acta. 291-317 (2012).
16. Gaspar MM, Radomska A, Gobbo OL, Bakowsky U, Radomski MW, Ehrhardt C. Targeted delivery of transferrin-conjugated liposomes to an orthotopic model of lung cancer in nude rats. J. Aerosol Med. Pulm. Drug Deliv. 25(6), 310-318 (2012).
17. Pruthi J, Mehra NK, Jain NK. Macrophages targeting of Amphotericin B loaded mannosylated carbon nanotubes. J. Drug Target. 20(7), 593-604 (2012).
18. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim. Biophys. Acta. 1770, 681-686 (2007).
19. Almasan A, Ashkenazi A. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 14, 337-348 (2003).
20. El-Zawahry A, McKillop J, Voelkel-Johnson C. Doxorubicin increases the effectiveness of Apo2L/TRAIL for tumor growth inhibition of prostate cancer xenografts. BMC Cancer 5, 1-9 (2005).
21. Bae S, Ma K, Kim TH et al. Doxorubicin-loaded human serum albumin nanoparticles surface-modified with TNF-related apoptosis-inducing ligand and transferrin for targeting multiple tumor types. Biomaterials 33, 1536-1546 (2012).
22. Lodhi N, Mehra NK, Jain NK. Dexamethasone conjugated multi walled carbon nanotubes: development and characterization. J. Drug Target. 21(1), 67-76 (2013).
23. Jain AK, Mehra NK, Lodhi N et al. Carbon nanotubes and their toxicity. Nanotoxicology 1(3), 167-197 (2007).
24. Mehra NK, Jain AK, Lodhi N et al. Challenges in the use of carbon nanotubes for biomedical application. Crit. Rev. Ther. Drug Carr. Syst. 25(2), 169-206 (2008).
25. Wilner SE, Wengerter B, Maier K et al. An RNA alternative to human transferrin: a new tool for targeting human cells. Mol. Ther. Nucleic Acids 1, e21(2012).
26. Pun SH, Tack F, Bellocq NC et al. Targeted delivery of RNA cleaving DNA enzyme (DNAzyme) to tumor tissue by transferrin-modified, cyclodextrin-based particles. Cancer Biol. Ther. 7, 31-41 (2004).
27. Habashy HO, Powe DG, Staka CM et al. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen. Breast Cancer Res. Treat. 119, 283-293 (2010).
28. Hong M, Zhu S, Jiang Y et al. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J. Control. Release 141, 22-29 (2010).
29. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 33(15), 3899-3908 (2012).
30. Zheng Y, Yu B, Weecharangsan W et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7a-APTADD to breast cancer cells. Int. J. Pharm. 390, 234-241 (2010).
31. Han L, Huang R, Li J, Liu S, Huang S, Jiang C. Plasmid pORF-hTRAIL and doxorubicin co-delivery targeting to tumor using peptide-conjugated polyamidoamine dendrimer. Biomaterials 32, 1242-1252 (2011).
32. He H, Li Y, Jia XR et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials 32(2), 478-487 (2011).
33. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int. J. Pharm. 329, 94-102 (2007).
34. Jiang YY, Liu C, Hong MH, Zhu SJ, Pei YY. Tumor cell targeting of transferrin-PEG-TNF-α conjugate via a receptor-mediated delivery system: design, synthesis, and biological evaluation. Bioconjug. Chem. 18, 41-49 (2007).
35. Mendonca LS, Fimino F, Moreira JN, Pedroso de Lima MC, Simoes S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or as ODN for chronic myeloid leukemia treatment. Bioconjug. Chem. 21(1), 167-168 (2010).
36. Koppu S, Oh YJ, Edrada-Ebel R et al. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA. J. Control. Release 143(2), 215-221 (2010).
37. Pang Z, Gao H, Yu Y et al. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with doxorubicin. Bioconjug. Chem. 22, 1171-1118 (2011).
38. Zhang Y, Hagedorn CH, Wang L. Role of nuclear receptor SHP in metabolism and cancer. Biochim. Biophys. Acta. 1812(8), 893-908 (2011).
39. Hu K, Li J, Shen Y et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J. Control. Release 134, 55-61 (2009).
40. Chen H, Tang L, Qin Y et al. Lactoferrin-modified procationic liposomes as a novel drug carrier for brain delivery. Eur. J. Pharm. Sci. 40, 94-102 (2010).
41. Wei M, Xu Y, Zou Q et al. Hepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrin. Eur. J. Pharm. Sci. 46, 131-141 (2012).
42. Huang R, Ke W, Liu Y, Jiang C, Pe Y. The use of lactoferrin as a ligand for targeting the poly (amido amine) based gene delivery system to the brain. Biomaterials 29(2), 238-246 (2008).
43. Ji B, Maeda J, Higuchi M et al. Pharmacokinetics and brain uptake of lactoferrin in rats. Life. Sci. 78(8), 851-855 (2006).
44. Xie H, Zhu Y, Jiang W et al. Lactoferrin-conjugated superparamagn etic iron oxide nanoparticles as a specific MRI contrast agent for detection of brain glioma in vivo. Biomaterials 32, 495-502 (2011).
45. Chen H, Qin Y, Zhang Q et al. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur. J. Pharm. Sci. 44, 164-173 (2011).
46. Kurmi BD, Gajbhiye V, Kayat V, Jain NK. Lactoferrin conjugated dendritic nanoconstructs for lung targeting of methotrexate. J. Pharm. Sci. 100(6), 2311-2320 (2011).
47. Jin L, Li Y. Structural and functional insights into nuclear receptor signaling. Adv. Drug Deliv. Rev. 62, 1218-1226 (2010).
48. Willson TM, Moore JT. Genomics versus orphan nuclear receptors-a half-time report. Mol. Endocrinol. 16, 1135-1144 (2002).
49. Khorasanizadeh S, Rastinejad F. Nuclear-receptor interactions on DNA-response elements. Trends Biochem. Sci. 26, 384-390 (2001).
50. Yemelyanoy A, Bhalla P, Yang X et al. Differential targeting of androgen and glucocorticoid receptors induces ER stress and apoptosis in prostate cancer cells: a novel therapeutic modality. Cell Cycle 11(2), 395-406 (2012).
51. Zollner G, Wagner M, Trauner M. Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. Pharmacol. Ther. 126(3), 228-243 (2010).
52. Dao KL, Sawant RR, Adam Hendricks J, Ronga V, Torchilin VP, Hanson RN. Design, synthesis, and initial biological evaluation of a steroidal anti-estrogen-doxorubicin bioconjugate for targeting estrogen receptor-positive breast cancer cells. Bioconjug. Chem. 23(4), 785-795 (2012).
53. Wong MY, Chiu GN. Simultaneous liposomal delivery of quercetin and vincristine for enhanced estrogen receptor-negative breast cancer treatment. Anticancer Drugs 21(4), 401-410 (2010).
54. Taheri A, Dinarvand R, Atyabi F et al. Enhanced anti-tumoral activity of methotrexate-human serum albumin conjugated nanoparticles by targeting with luteinizing hormone-releasing hormone (LHRH) peptide. Int. J. Mol. Sci. 12(7), 4591-4608 (2011).
55. Ni M, Chen Y, Lim E et al. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell 20(1), 119-131 (2011).
56. Jain S, Jain A, Gulbake A, Shilpi S, Khare P. Steroid coupled liposomes for targeted delivery to tumor. Ther. Deliv. 1(2), 345-357 (2010).
57. Brem AS. Targeted activated mineralocorticoid receptor: occam's razor revisted. Kidney Int. 82, 619-620 (2012).
58. Ahmad N, Kumar R. Steroid hormone receptors in cancer development: a target for cancer therapeutics. Cancer Lett. 300(1), 1-9 (2011).
59. Schmidt LJ, Tindall DJ. Steroid 5 a-reductase inhibitors targeting BPH and prostate cancer. J. Steroid Biochem. Mol. Biol. 125(1-2), 32-38 (2011).
60. Pearce KH, Iannone MA, Simmons CA, Gray JG. Discovery of novel nuclear receptor modulating ligands: an integral role for peptide interaction profiling. Drug Discov. Today. 9(17), 741-751 (2004).
61. McNamara KM, Takagi YK, Suzuki YM, Sasano H. Androgen receptor in triple negative breast cancer. J. Steroid Biochem. Mol. Biol. 133, 66-76 (2013).
62. Mukherjee A, Narayan KP, Pal K et al. Selective cancer targeting via aberrant behavior of cancer cell-associated glucocorticoid receptor. Mol. Ther. 17(4), 623-631 (2009).
63. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J. Biol. Chem. 271, 12687-12690 (1996).
64. Mandrekar-Colucci S, Landreth GE. Nuclear receptors as therapeutic targets for alzheimer's disease. Expert Opin. Ther. Targets 15(9), 10850-11097 (2011).
65. Pan L, He Q, Liu J et al. Nuclear-targeted drug delivery of TAT peptide-conjugated monodisperse mesoporous silica nanoparticles. J. Am. Chem. Soc. 134(13), 5722-5725 (2012).
66. Hui EK, Boado RJ, Pardridge WM. Tumor necrosis factor receptor-igG fusion protein for targeted drug delivery across the human blood-brain barrier. Mol. Pharm. 6(5), 1536-1543 (2009).
67. Xiang H, Nguyen CB, Kelley SK, Dybdal N, Escandón E. Tissue distribution, stability, and pharmacokinetics of Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispos. 32, 1230-1238 (2004).
68. Ai, S, Duan J, Liu X, Bock S, Tian Y, Huang Z. Biological evaluation of a novel doxorubicin-peptide conjugate for targeted delivery to EGF receptor-overexpressing tumor cells. Mol. Pharm. 8, 375-386 (2011).
69. Szliszka E, Jaworska D, Ksek M, Czuba ZP, Krol W. Targeting death receptor TRAIL-R2 by chalcones for TRAIL-induced apoptosis in cancer cells. Int. J. Mol. Sci. 13(11), 15343-15359 (2012).
70. Yao R, Sui A, Wang Z et al. Induction of non-small cell lung carcinoma apoptosis using soluble RGD-TRAIL by targeting the integrin receptor of tumor cells. Mol. Med. Report 6(6), 1355-1360 (2012).
71. Ventura E, Balza E, Borsi L et al. Selective targeted delivery of the TNF-alpha receptor p75 and uteroglobin to the vasculature of inflamed tissues: a preliminary report. BMC Biotechnol. 11, 104-112 (2011).
72. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nature Rev. Drug Discov. 9, 482-493 (2010).
73. Dutta PR, Maity A. Cellular responses to EGFR inhibitors and their relevance to cancer therapy. Cancer Lett. 254, 165-177 (2007).
74. Herbst RS. Review of epidermal growth factor receptor biology. Int. J. Radiat. Oncol. Biol. Phys. 59, 21-26 (2004).
75. Harari PM, Allen GW, Bonner JA. Biology of interactions: antiepidermal growth factor receptor agents. J. Clin. Oncol. 25, 4057-4065 (2007).
76. Okamoto I. Epidermal growth factor receptor in relation to tumor development: EGFR-targeted anticancer therapy. FEBS J. 277, 309-315 (2010).
77. Schneider MR, Wolf E. The epidermal growth factor receptor ligands at a glance. J. Cell. Physiol. 218, 460-466 (2009).
78. Cooke RM, Wilkinson AJ, Baron M et al. The solution structure of human epidermal growth factor. Nature 327, 339-341 (1987).
79. Medina OP, Pillarsetty N, Glekas A et al. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J. Control. Release 149, 292-298 (2011).
80. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J. Natl Cancer Inst. 95 (12), 851-867 (2003).
81. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21(14), 2787-2799 (2003).
82. Schwechheimer K, Huang S, Cavenee WK. EGFR gene amplification- rearrangement in human glioblastomas. Int. J. Cancer. 62(2), 145-148 (1995).
83. Wu G, Barth RF, Yang W et al. Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjug. Chem. 15, 185 (2004).
84. Barth RF, Wu G, Yang W et al. Neutron capture therapy of epidermal growth factor (+) gliomas using boronated cetuximab (IMC-C225) as a delivery agent. Appl. Radiat. Isot. 61, 899 (2004).
85. Hussain M, Shchepinov M, Sohail M et al. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides. J. Control. Release 99, 139 (2004).
86. Hu F, Wu X, Du Y, You J, Yuan H. Cellular uptake and cytotoxicity of shell crosslinked stearic acid-grafted chitosan oligosaccharide micelles encapsulating doxorubicin. Eur. J. Pharm. Biopharm. 69, 117-125 (2008).
87. Park JH, Kwon S, Lee M et al. Self-assembled nanoparticles based on glycol chitosan bearing hydrophobic moieties as carriers for doxorubicin: in vivo biodistribution and anti-tumor activity. Biomaterials 27, 119-126 (2006).
88. Ishida O, Maruyama K, Tanahashi H et al. Liposomes bearing polyethylene glycol-coupled transferrin with intracellular targeting property to the solid tumors in vivo. Pharm. Res. 18, 1042-1048 (2001).
89. Jabr-Milane LS, Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34, 592-602 (2008).
90. Park S, Yoo HS. In vivo and in vitro anti-cancer activities and enhanced cellular uptakes of EGF fragment decorated doxorubicin nano-aggregates. Int. J. Pharm. 383, 178-185 (2010).
91. Ciardiello F, Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin. Cancer Res. 7, 2958-2970 (2001).
92. Rebeca AM, Elaine VM, Margaret RK et al. EGFR pathway polymorphisms and bladder cancer susceptibility and prognosis. Carcinogenesis 30, 1155-1160 (2009).
93. Hoeling T, Siperstein AE, Clark OH, Duh QY. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo. J. Clin. Endocrinol. Metab. 79, 401-408 (2009).
94. Bhirde AA, Patel V, Gavard J et al. Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano 3(2), 307 (2009).
95. Bhirde AA, Patel S, Sousa AA et al. Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond.) 5(10), 1535 (2010).
96. Wang S, Chen C, Meng Y et al. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody. Cancer Lett. 325, 214-219 (2012).
97. Lam L, McAndrew N, Yee M, Fu T, Tchou JC, Zhang H. Challenges in the clinical utility of the serum test for HER2 ECD. Biochim. Biophys. Acta. 1826(1), 199-208 (2012).
98. Sutera TM, Cook-Bruns N, Barton C. Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast 13, 173-183 (2004).
99. Vlahopoulos S, Gritzapis AD, Perez SA et al. Mannose addition by yeast Pichia Pastoris on recombinant HER-2 protein inhibits recognition by the monoclonal antibody herceptin. Vaccine 27, 4704-4708 (2009).
100. Kirpotin DB, Drummond DC, Shao Y et al. Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res. 66(13), 6732-6740 (2006).
101. Romond EH, Perez, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
102. Bullock K, Blackwell K. Clinical efficacy of taxane-trastuzumab combination regimens for HER-2-positive metastatic breast cancer. Oncologist 13, 515-525(2008).
103. Mi Y, Liu X, Zhao J, Ding J, Feng SS. Multimodality treatment of cancer with herceptin conjugated, thermomagnetic iron oxides and docetaxel loaded nanoparticles of biodegradable polymers. Biomaterials 33, 7519-7529 (2012).
104. Pritchard KI, Shepherd LE et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N. Engl. J. Med. 354, 2103-2111 (2006).
105. Hayes DF, Thor AD, Dressler LG et al. Cancer and leukemia Group B (CALGB) Investigators: HER2 and response to paclitaxel in node-positive breast cancer. N. Engl. J. Med. 357, 496-1506 (2007).
106. Strohecker AM, Yehiely F, Chen F, Cryns VL. Caspase cleavage of HER-2 releases a bad-like cell death effector. J. Biol. Chem. 283, 18269-18282 (2008).
107. Mi Y, Liu YT, Guo YJ, Feng SS. Herceptin(R)-conjugated nanocarriers for tar-geted imaging and treatment of HER2-positive cancer. Nanomedicine (Lond.) 6, 311-312 (2011).
108. Liu Y, Li K, Liu B, Feng SS. A strategy for precision engineering of nanoparticles of biodegradable copolymers for quantitative control of targeted drug delivery. Biomaterials 31, 9145-9155 (2010).
109. Zhao J, Mi Y, Liu YT, Feng SS. Quantitative control of targeting effect of anticancer drugs formulated by ligand-conjugated nanoparticles of biodegradable copolymer blend. Biomaterials 33, 1948-1958 (2012).
110. Cambi A, Figdor CG. Dual function of C-type lectin-like receptors in the immune system. Curr. Opin. Cell. Biol. 15, 539-546 (2003).
111. Agrawal P, Gupta U, Jain NK. Glycoconjugated peptide dendrimers-based nanoparticulate system for the delivery of chloroquine phosphate. Biomaterials 28, 3349-3359 (2007).
112. Dennis JW, Granovsky M, Warren CE. Glycoprotein glycosylation and cancer progression. Biochim. Biophys. Acta. 1473, 21-34 (1999).
113. Kesharwani P, Tekade RK, Gajbhiye V, Jain NK. Cancer targeting potential of some ligand-anchored poly(propylene-imine) dendrimers: a comparison. Nanomedicine 7(3), 295-304 (2011).
114. Jain AK, Mehra NK, Lodhi N et al. Galactose conjugated multi walled carbon nanotubes: development and characterization. Nanomedicine 5(4), 432-442 (2009).
115. Agashe HB, Babbar AK, Jain S et al. Investigations on biodistribution of 99m. technetium-labeled carbohydrate-coated poly (propylene imine) dendrimers. Nanomedicine 3(2), 120-127 (2007).
116. Dutta T, Agashe HB, Garg M et al. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Target. 15(1), 89-98 (2007).
117. Davis BG, Robinson MA. Drug delivery systems based on sugar macromolecule conjugates. Curr. Opin. Drug Discov. Dev. 5, 279-288 (2002).
118. Mishra V, Gupta U, Jain NK. Surface engineered dendrimers: a solution for toxicity issue. J. Biomat. Sci. 20, 141-166 (2009).
119. Nahar M, Dubey V, Mishra D. In vitro evaluation of surface functionalized gelatin nanoparticles for macrophage targeting in the therapy of visceral leishmaniasis. J. Drug Target. 18(2), 93-105 (2010).
120. Madani SY, Tan A, Dwek M, Seifalian AM. Functionalization of single-walled carbon nanotubes and their binding to cancer cells. Int. J. Nanomed. 7, 905-914 (2012).
121. Ruoslahti E. Fibronectin and its integrin receptors in cancer. Adv. Cancer Res. 76, 1-2 (1999).
122. Reddy KVR, Mangale SS. Integrin receptors: the dynamic modulators of endometrial function. Tissue Cell. 35, 260-273 (2003).
123. Dijkgraaf I, Rijnders AY, Soed A et al. Synthesis o f DOTA-conjugated multivalent cyclic-RGD peptide dendrimers via 1,3-dipolar cycloaddition and their biological evaluation: implications for tumor targeting and tumor imaging purposes. Org. Biomol. Chem. 5, 935-944 (2007).
124. Call-Culbreath KD, Zutter MM. Collagen receptor integrins: rising to the challenge. Curr. Drug Target 9, 139-149 (2008).
125. Schiffelers RM, Koning GA, Ten Hagen TLM et al. Anti-tumor efficacy of tumor vasculature-targeted liposomal doxorubicin. J. Control. Release 91, 115-122 (2003).
126. Schiffelers RM, Storm G. Liposomal nanomedicines as anticancer therapeutics: beyond targeting tumor cells. Int. J. Pharm. 364, 258-264 (2008).
127. Hood JD, Bednarski M, Frausto R et al. Tumor regression by targeted gene delivery to the neovasculature. Science 296(5577), 2404-2407 (2002).
128. Lin RY, Dayananda K, Chen TJ et al. Targeted RGD nanoparticles for highly sensitive in vivo integrin receptor imaging. Contrast Media Mol. Imaging 7(1), 7-18 (2012).
129. Nasongkla N, Shuai X, Ai H et al. cRGDfunctionalized polymer micelles for targeted doxorubicin delivery. Angew. Chem. Int. Ed. Engl. 43(46), 6323-6327(2004).
130. Waite CL, Roth CM. PAMAM-RGD conjugates enhance siRNA delivery through a multicellular spheroid model of malignant glioma. Bioconjug. Chem. 20, 19081916 (2009).
131. Xiong XB, Huang Y, Lu WL et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J. Control. Release 107, 262-275 (2005).
132. Xiong XB, Huang Y, Lu WL et al. Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: in vitro and in vivo. J. Pharm. Sci. 94, 1782-1793 (2005).
133. Li Q, Xu W. Novel anticancer targets and drug discovery in post genomic age. Curr. Med. Chem. Anticancer Agents 5, 53-63 (2005).
134. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74, 467-473 (2010).
135. Zhang L, Zhu S, Qian L, Pei Y, Qiu Y, Jiang Y. RGD-modified PEG-PAMAMDOX conjugates: in vitro and in vivo studies for glioma. Eur. J. Pharm. Biopharm. 79, 232-240 (2011).
136. Lee S, Kim J, Shim G et al. Tetraiodothyroacetic acid-tagged liposomes for enhanced delivery of anticancer drug to tumor tissue via integrin receptor. J. Control. Release 164(2), 213-220 (2012).
137. Shuhendler AJ, Prasad P, Leung M, Rauth AM, DaCosta RS, Wu XY. A novel solid lipid nanoparticles formulation for active targeting to tumor av b3 integrin receptors reveals cyclic RGD as a double-edged sword. Adv. Healthc. Mater. 1(5), 600-608 (2012).
138. Jager NA, Teteloshvili N, Zeebregts CJ, Westra J, Bijl M. Macrophage folate receptor-β (FR-b) expression in auto-immune inflammatory rheumatic diseases: a forthcoming marker for cardiovascular risk? Autoimmun. Rev. 11, 621-626 (2012).
139. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticles targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 65 (12), 5317-5324 (2005).
140. Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist. Updat. 15, 183-210 (2012).
141. Ulbrich K, Michaelis M, Rothweiler F. Interaction of folate-conjugated human serum albumin (HSA) nanoparticles with tumour cells. Int. J. Pharm. 406, 128-134 (2011).
142. Ma Y, Sadoqi M, Shao J. Biodistribution of indocyanine green-loaded nanoparticles with surface modifications of PEG and folic acid. Int. J. Pharm. 436, 25-31 (2012).
143. Holm C, Schou LN, Babol AJ et al. The interrelationship between ligand binding and self-association of the folate binding protein. The role of detergent-tryptophan interaction. Biochim. Biophys. Acta. 1330-1339 (2011).
144. Holm J, Lawaetz AJ, Hansen SI. Ligand binding induces a sharp decrease in hydrophobicity of folate binding protein assessed by 1-anilinonaphthalene-8- sulphonate which suppresses self-association of the hydrophobic apoprotein. Biochem. Biophys. Res. Comm. 425(1), 19-24 (2012).
145. Pan XQ, Zheng X, Shi G, Wang H, Ratnam M, Lee RJ. Strategy for the treatment of acute myelogenous leukemia based on folate receptor beta-targeted liposomal doxorubicin combined with receptor induced using all-trans-retinoic acid. Blood 100(2), 594-602 (2002).
146. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1233, 134-144 (1995).
147. Xiang G, Wu J, Liu Z, Liu Z, Lee RJ. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int. J. Pharm. 356, 29-36 (2008).
148. Tekade RK, Dutta T, Gajbhiye V, Jain NK. Exploring dendrimer towards dual drug delivery: pH responsive simultaneous drug-release kinetic. J. Microencapsul. 26(4), 287-296 (2009).
149. Tekade RK, Dutta T, Tyagi A, Bharti AC, Das BC, Jain NK. Surface engineered dendrimers for dual drug delivery: a receptor up-regulation and enhanced cancer targeting strategy. J. Drug Target. 16(10), 758-772 (2008).
150. Shi X, Wang SH, Shen M et al. Multifunctional dendrimer-modified multiwalled carbon nanotubes: synthesis, characterization, and in vitro cancer cell targeting and imaging. Biomacromolecules 10, 1744-1750 (2009).
151. Zhang X, Meng L, Lu Q, Fei Z, Dyson PJ. Targeted delivery and controlled release of doxorubicin to cancer cells using modified single wall carbon nanotubes. Biomaterials 30, 6041-6047 (2009).
152. Huang H, Yuan Q, Shah JS, Misra RDK. A new family of folate-decorated and carbon nanotube-mediated drug delivery system: synthesis and drug delivery response. Adv. Drug Deliv. Rev. 63, 1332-1339 (2011).
153. Ji Z, Lin G, Lu Q et al. Targeted therapy of SMMC-7721 liver cancer in vitro and in vivo with carbon nanotubes based drug delivery system. J. Colloid Interface Sci. 365, 143-149 (2012).
154. Yoo MK, Park IK, Lim HT. Folate-PEG-superparamagnetic iron oxide nanoparticles for lung cancer imaging. Acta. Biomater. 8, 3005-3013 (2012).
155. Li X, Zhou H, Yang L et al. Enhancement of cell recognition in vitro by dual-ligand cancer targeting gold nanoparticles. Biomaterials 32, 2540-2545 (2011).
156. Li H, Lu Y, Piao L et al. Targeting human clonogenic acute myelogenous leukemia cells via folate conjugated liposomes combined with receptor modulation by all-trans retinoic acid. Int. J. Pharm. 402, 57-63 (2010).
157. Zhao P, Wang H, Yu M et al. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: in vitro and in vivo evaluation. Pharm. Res. 27(9), 1914-1926 (2010).
158. Zhang C, Zhao LQ, Dong YF, Zhang XY, Lin J, Chen Z. Folate-mediated poly(3hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur. J. Pharm. Biopharm. 76, 10-16 (2010).
159. Tse C, Zohdy MJ, Ye JY, O'Donnell M, Lesniak W, Balogh L. Enhanced optical breakdown in KB cells labeled with folate-targeted silver-dendrimer composite nanodevices. Nanomedicine 7(1), 97-106 (2011).
160. Wang Y, Cao X, Guo R et al. Targeted delivery of doxorubicin into cancer cells using a folic acid-dendrimer conjugate. Polym. Chem. 2, 1754-1760 (2011).
161. Li MH, Choi SK, Thomas TP et al. Dendrimer-based multivalent methotrexate as dual acting nanoconjugates for cancer cell targeting. Eur. J. Med. Chem. 47, 560-572 (2012).
162. Malhi SS, Budhiraja A, Arora S et al. Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell folate receptor targeted mitocancerotropic liposomes. Int. J. Pharm. 432(1-2), 63-74 (2012).
163. Venishetty VK, Komuravelli R, Kuncha M, Sistla R, Diwan PV. Increase brain uptake of docetaxel and ketoconazole loaded folate-grafted solid lipid nanoparticles. Nanomedicine 9(1), 111-121 (2012).
164. Zong H, Thomas TP, Lee KH et al. Bifunctional PAMAM dendrimer conjugates of folic acid and methotrexate with defined ratio. Biomacromolecules 13(4), 982-991 (2012).
165. Wang S, Luo Y, Zeng S et al. Dodecanol-poly(d,l-lactic acid)-b-poly (ethylene glycol)-folate (Dol-PLA-PEG-FA) nanoparticles: Evaluation of cell cytotoxicity and selecting capability in vitro. Colloids Surf. B Biointerfaces 102, 130-135 (2013).
166. Wilkinson K, ElKhoury J. Microglial scavenger receptors and their roles in the pathogenesis of alzheimer's disease. Int. J. Alzheimer's Dis. 1-10 (2012).
167. Graversen JH, Svendsen P, Dagbes-Hansen F et al. Targeting the hemoglobin scavenger receptor CD163 in macrophages highly increases the anti-inflammatory potency of dexamethasone. Mol. Ther. 20(8), 1550-1558(2012).
168. Goldstein JL, Ho YK, Basu SK, Brown MS. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Natl Acad. Sci. USA 76(1), 333-337 (1979).
169. Sohaebuddin SK, Thevenot PT, Baker D, Eaton JW, Tang L. Nanomaterial cytotoxicity is composition, size, and cell type dependent. Part Fibre Toxicol. 7, 22 (2010).
170. Wang X, Guo J, Chen T et al. Multi-walled carbon nanotubes induce apoptosis via mitochondrial pathway and scavenger receptor. Toxicol. In Vitro. 26, 799-806 (2012).
171. Hamilton RF, de Villiers WJ, Holian A. Class A type II scavenger receptor mediates silica-induced apoptosis in Chinese hamster ovary cell line. Toxicol. Appl. Pharm. 162, 100-106 (2000).
172. Elgrabli D, Abella-Gallart S, Robidel F, Rogerieux F, Boczkowski J, Lacroix G. Induction of apoptosis and absence of inflammation in rat lung after intratracheal instillation of multiwalled carbon nanotubes. Toxicology 253, 131-136 (2008).
173. Patlolla A, Knighten B, Tchounwou P. Multi-walled carbon nanotubes induce cytotoxicity, genotoxicity and apoptosis in normal human dermal fibroblast cells. Ethnobiol. Dis. 20, 65-72 (2010).
174. Hu X, Cook S, Wang P, Hwang HM, Liu X, Williams QL. In vitro evaluation of cytotoxicity of engineered carbon nanotubes in selected human cell lines. Sci. Total Environ. 408, 1812-1817 (2010).
175. Laurent TC, Fraser JRE. Hyaluronan. FASEB J. 6, 2397-1404 (1992).
176. Eriksson S, Fraser JRE, Laurent TC, Pertoft H. Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp. Cell Res. 144, 223-228 (1983).
177. Culty M, Nguyen HA, Underhill CB. The hyaluronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J. Cell. Biol. 116 (4), 1055-1062 (1992).
178. Rodriguez Hurtadoa I, Stewarta AJ, Wolfea DF, Caldwella FJ, Harrieb M, Whitley EM. Immunolocalization of the hyaluronan receptor CD44 in the reproductive tract of the mare. Theriogenology 75, 276-286 (2011).
179. Jackson DG. Immunological functions of hyaluronan and its receptors in the lymphatics. Immunol. Rev. 230, 216-231 (2009).
180. Johnson P, Ruffell B. CD44 and its role in inflammation and inflammatory diseases. Inflamm. Allergy Drug Target 8, 208-220 (2009).
181. Evanko SP, Tammi MI, Tammi RH, Wight TN. Hyaluronan-dependent
182. Shen Y, Wang B, Lu Y, Ouahab A, Li Q, Tu J. A novel tumor-targeted delivery system with hydrophobized hyaluronic acid-spermine conjugates (HHSCs) for efficient receptor-mediated siRNA delivery. Int. J. Pharm. 414(1-2), 233-243 (2011).
183. Upadhyay KK, Bhatt AN, Mishra AN et al. The intracellular drug delivery and antitumor activity of doxorubicin loaded poly (g-benzyl l-glutamate)-b- hyaluronan polymersomes. Biomaterials 31, 2882-2892 (2010).
184. Upadhyay KK, Mishra AN, Chuttani K et al. The in vivo behavior and antitumor activity of doxorubicin-loaded poly (g-benzyl l-glutamate)-b- Hyaluronan polymersomes in Ehrlich ascites tumor-bearing BalB/c mice. Nanomedicine 8(1), 71-80 (2012).
185. Cho HJ, Yoon IS, Yoon HY et al. Polyethylene glycol-conjugated hyaluronic acidceramide self-assembled nanoparticles for targeted delivery of doxorubicin. Biomaterials 33(4), 1190-1200 (2012).
186. Wu JL, Liu CG, Wang XL, Huang ZH. Preparation and characterization of nanoparticles based on histidine-hyaluronic acid conjugates as doxorubicin carriers. J. Mater. Sci. Mater. Med. 23(8), 1921-1929 (2012).
187. Saravanakumar G, Choi KY, Yoon HY et al. Hydrotropic hyaluronic acid conjugates: synthesis, characterization, and implications as a carrier of paclitaxel. Int. J. Pharm. 394, 154-161 (2010).
188. Rasmussen SG, Choi HJ, Fung JJ et al. Structure of a nanobody-stabilized active state of the b2-adrenoceptor. Nature 469 (7329), 175-180 (2011).
189. Rosenbaum DM, Zhang C, Lyons JA et al. Structure and function of an irreversible agonist-b2 adrenoceptor complex. Nature 469 (7329), 236-240 (2011).
190. Legg K, G protein-coupled receptors: case builds for TGR5 as metabolic syndrome target. Nat. Rev. Drug Discov. 11, 22-23 (2012).
191. Warne T, Moukhametzianov R, Baker JG et al. The structural basis for agonist and partial agonist action on a b1-adrenergic receptor. Nature 469 (7329), 241-244 (2011).
192. Kaminskas LM, McLeod VM, Kelly BD et al. A comparison of changes to doxorubicin pharmacokinetics, antitumor activity and toxicity mediated by PEGylated dendrimer and PEGylated liposome drug delivery systems. Nanomedicine 8(1), 103-111 (2012).
193. Pi M, Quarles LD. GPCR6A regulates prostate cancer progression. Prostate 72(4), 399-409 (2012).
194. Dreaden EC, Gryder BE, Austin LA et al. Antiandrogen gold nanoparticles dual-target and overcome treatment resistance in hormone-insensitive prostate cancer cells. Bioconjug. Chem. 23, 1507-1512 (2012).